148P Phase III study of everolimus or placebo in addition to adjuvant hormone therapy for high risk early breast cancer: Subgroup analysis of the UCBG UNIRAD trial

Autor:	Jérôme Lemonnier, Audrey Mailliez, M.A. Mouret Reynier, Fabrice Andre, J-P. Jacquin, Florence Dalenc, M. Brunt, J-L Canon, A-C. Hardy-Bessard, L. Kaluzinski, Paul-Henri Cottu, J. Grenier, Judith M Bliss, D. Allouache, Thomas Bachelot, Sylvie Chabaud, Sylvie Giacchetti, David Cameron, E. Legouffe, Philippe Barthélémy
Rok vydání:	2021
Předmět:	Oncology medicine.medical_specialty Everolimus business.industry medicine.medical_treatment Subgroup analysis Hematology Placebo Internal medicine medicine Hormone therapy business Adjuvant Early breast cancer medicine.drug
Zdroj:	Annals of Oncology. 32:S425
ISSN:	0923-7534
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::a410a5a61acc34ec3cd51cbf307b51cb https://doi.org/10.1016/j.annonc.2021.08.429 Zobrazit plný text záznamu